INmune Bio【INMB】銘柄情報

INmune Bio Inc (INMB) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

1.715

( 2.08% )

買値

1.71

売値

1.72

出来高

244,424

1.639 日の範囲 1.7401

1.09 52 週間の範囲 3.244

時価総額

45.594M

前日終値

1.68

始値

1.72

時刻

1.715

最終取引時間

23:26:08

財務取引量

US$ 412,892

VWAP

1.6892

平均取引量 (3 か月)

US$ 618,440

発行済株式数

26,585,258

配当利回り

PER

-1

1 株当たり利益 (EPS)

-1.61

歳入

純利益

-41.6M

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation... INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer’s disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.inmunebio.com

本社

Boca Raton, United States

設立

2026

INmune Bio Inc is listed in the Healthcare sector of the ナスダック市場 with ticker INMB. The last closing price for INmune Bio was US$1.68. Over the last year, INmune Bio shares have traded in a share price range of US$ 1.09 to US$ 3.244.

INmune Bio currently has 26,585,258 shares in issue. The market capitalisation of INmune Bio is US$45.59 million. INmune Bio has a price to earnings ratio (PE ratio) of -1.00.

Form 8-K - Current report

INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion

Secures Global Framework for Composition-of-Matter and Method-of-Treatment Claims Covering Lead Program...

INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™

Approval of pediatric strategy validates clinical data package and accelerates the regulatory path for...

Form 8-K - Current report

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

MHRA minutes from May 12 pre-MAA Scientific Advice meeting confirm agreement across all questions covering CMC...

Form 8-K - Current report

INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial

XPro1595 showed a highly significant treatment effect in the full mITT population (p=0.0028; d=0.46; n=200...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Canada NewsWire SAN FRANCISCO, May...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.345	25.1824817518	1.37	1.7401	1.3	3674700	1.49852746	CS
4	0.405	30.9160305344	1.31	1.7401	1.2	1169488	1.46815336	CS
12	0.435	33.984375	1.28	1.79	1.155	645454	1.47619821	CS
26	0.095	5.86419753086	1.62	1.8	1.09	526509	1.43651594	CS
52	-0.355	-17.1497584541	2.07	3.244	1.09	798153	2.07504648	CS
156	-7.475	-81.3384113166	9.19	14.74	1.09	534796	3.9718853	CS
260	-16.375	-90.5196241017	18.09	30.37	1.09	387758	5.86033295	CS